To the Editor.
—I was surprised to read the case report by McDonald and colleagues1 in the May 1989 issue of the Archives. While I do not understand how the Investigational Device Exemption granted by the Food and Drug Administration to Dr Trokel could have been used by the authors, the procedure was stated to have been performed as "part of the early human safety efficacy 'blind eye' trials."The authors referred to the patient as having a "putatively blind eye." They indicated that they were surprised to discover that her blindness was functional (I do not know what they mean by "physiological blindness").The authors stated that "we believed, in good faith, that she was organically blind." Yet the patient had, according to the report, "no Marcus Gunn pupil." Her retina was attached and her optic nerve was pink.I do not believe that the authors can make
Weinstein GW. Functional Blindness in Photorefractive Keratectomy. Arch Ophthalmol. 1989;107(11):1563. doi:10.1001/archopht.1989.01070020641001